{"DataElement":{"publicId":"3008833","version":"1","preferredName":"Disease or Disorder Best Outcome of Therapy Amyloidosis Neuropathy Status Type","preferredDefinition":"A description of the best peripheral neuropathy response to therapy for amyloidosis.","longName":"2946463v1.0:3008813v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2946463","version":"1","preferredName":"Disease or Disorder Best Outcome of Therapy","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Having the most positive qualities._The result of therapy for a given disease or condition in a patient or group of patients.","longName":"2404658v1.0:3194600v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2404658","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0651-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"PWEST","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3194600","version":"1","preferredName":"Best Outcome of Therapy","preferredDefinition":"Having the most positive qualities.:The result of therapy for a given disease or condition in a patient or group of patients.","longName":"C25432:C18919","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Best","conceptCode":"C25432","definition":"Having the most positive qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome of Therapy","conceptCode":"C18919","definition":"The result of therapy for a given disease or condition in a patient or group of patients.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D80CD45-BE7A-5B19-E040-BB89AD430E80","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-03-02","modifiedBy":"ONEDATA","dateModified":"2011-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"747EBAC6-25E8-A734-E040-BB89AD43588E","latestVersionIndicator":"Yes","beginDate":"2009-09-26","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-09-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3008813","version":"1","preferredName":"Amyloidosis Neuropathy Status Type","preferredDefinition":"A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands._A disorder affecting the cranial nerves or the peripheral nervous system. It is manifested with pain, tingling, numbness, and muscle weakness. It may be the result of physical injury, toxic substances, viral diseases, diabetes, renal failure, cancer, and drugs._A condition or state at a particular time._Type; a subdivision of a particular kind of thing.","longName":"3008813v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Not assessed","valueDescription":"Not Done","ValueMeaning":{"publicId":"3104692","version":"1","preferredName":"Not Done","longName":"3104692v1.00","preferredDefinition":"Indicates a task, process or examination that has either not been initiated or not been completed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Done","conceptCode":"C49484","definition":"Indicates a task, process or examination that has either not been initiated or not been completed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"88084310-6796-6259-E040-BB89AD4311C3","latestVersionIndicator":"Yes","beginDate":"2010-06-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-02","modifiedBy":"RAGUNATHANU","dateModified":"2022-05-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"9D6E5B8F-2520-41BA-E040-BB89AD436453","beginDate":"2010-02-10","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-03-01","modifiedBy":"ONEDATA","dateModified":"2011-03-01","deletedIndicator":"No"},{"value":"Not evaluable","valueDescription":"Unevaluable","ValueMeaning":{"publicId":"3153578","version":"1","preferredName":"Unevaluable","longName":"3153578","preferredDefinition":"Unable to be evaluated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unevaluable","conceptCode":"C62222","definition":"Unable to be evaluated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93AC689E-5DB2-5D7A-E040-BB89AD430948","latestVersionIndicator":"Yes","beginDate":"2010-10-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-10-28","modifiedBy":"KUMMEROA","dateModified":"2023-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"9D6E5B8F-252A-41BA-E040-BB89AD436453","beginDate":"2010-02-10","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-03-01","modifiedBy":"ONEDATA","dateModified":"2011-03-01","deletedIndicator":"No"},{"value":"Not applicable","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F50F2369-A497-E6D0-E040-BB89AD434429","beginDate":"2014-03-20","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-03-20","modifiedBy":"ONEDATA","dateModified":"2014-03-20","deletedIndicator":"No"},{"value":"Progressive disease","valueDescription":"Progressive disease","ValueMeaning":{"publicId":"4241892","version":"1","preferredName":"Progressive disease","longName":"4241892","preferredDefinition":"Requires any of the following: 1) worsening of physical findings 2) worsening of EMG and/or NCV findings","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F50F2369-A4A1-E6D0-E040-BB89AD434429","latestVersionIndicator":"Yes","beginDate":"2014-03-20","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-03-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F50F2369-A4B9-E6D0-E040-BB89AD434429","beginDate":"2011-03-01","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-03-20","modifiedBy":"ONEDATA","dateModified":"2014-03-20","deletedIndicator":"No"},{"value":"No response / stable disease","valueDescription":"No response/stable disease","ValueMeaning":{"publicId":"4241891","version":"1","preferredName":"No response/stable disease","longName":"4241891","preferredDefinition":"Does not meet criteria for peripheral neuropathy response nor progressive disease","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F50F2369-A475-E6D0-E040-BB89AD434429","latestVersionIndicator":"Yes","beginDate":"2014-03-20","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-03-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"18BBC999-9CA1-120B-E050-BB89AD437EDA","beginDate":"2014-03-20","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-06-17","modifiedBy":"ONEDATA","dateModified":"2015-06-17","deletedIndicator":"No"},{"value":"Peripheral neuropathy response","valueDescription":"Peripheral neuropathy response","ValueMeaning":{"publicId":"4873951","version":"1","preferredName":"Peripheral neuropathy response","longName":"4873951","preferredDefinition":"Requires any of the following: 1) resolution of abnormal physical findings 2) resolution or improvement of abnormal EMG and/or NCV findings","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"18BD132C-CD5A-18CA-E050-BB89AD43205B","latestVersionIndicator":"Yes","beginDate":"2015-06-17","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-06-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"18BD132C-CD72-18CA-E050-BB89AD43205B","beginDate":"2011-03-01","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-06-17","modifiedBy":"ONEDATA","dateModified":"2015-06-17","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3008812","version":"1","preferredName":"Amyloidosis Neuropathy Status Type","preferredDefinition":"A group of diseases in which protein is deposited in specific organs (localized amyloidosis) or throughout the body (systemic amyloidosis). Amyloidosis may be either primary (with no known cause) or secondary (caused by another disease, including some types of cancer). Generally, primary amyloidosis affects the nerves, skin, tongue, joints, heart, and liver; secondary amyloidosis often affects the spleen, kidneys, liver, and adrenal glands.:A disorder affecting the cranial nerves or the peripheral nervous system.  It is manifested with pain, tingling, numbness, and muscle weakness.  It may be the result of physical injury, toxic substances, viral diseases, diabetes, renal failure, cancer, and drugs. -- 2004:A condition or state at a particular time.:Type; a subdivision of a particular kind of thing.","longName":"C2868:C4731:C25688:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amyloidosis","conceptCode":"C2868","definition":"A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Neuropathy","conceptCode":"C4731","definition":"A disorder affecting the cranial nerves or the peripheral nervous system. It manifests with pain, tingling, numbness, and muscle weakness. It may be the result of physical injury, toxic substances, viral diseases, diabetes, renal failure, cancer, and drugs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F3E1DA4-B32B-419D-E040-BB89AD4354A5","latestVersionIndicator":"Yes","beginDate":"2010-02-10","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-02-10","modifiedBy":"ONEDATA","dateModified":"2010-02-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F3E1DA4-B33C-419D-E040-BB89AD4354A5","latestVersionIndicator":"Yes","beginDate":"2010-02-10","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-02-10","modifiedBy":"NYCHM","dateModified":"2017-04-05","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964910","version":"1","longName":"2117r1: Amyloidosis Post-HSCT Data","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"amy_post_bst_perineur_rsp","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedDiagnosis:diseaseStatusCode ","type":"HCT_BRIDG","context":"NHLBI"},{"name":"PCDpost_amy_hema_organ_neuropathy_best_resp","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What is the best outcome of t","type":"Preferred Question Text","description":"What is the best outcome of therapy for amyloidosis peripheral neuropathy?","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:3008833","type":"BRIDG Mapping Path","description":"PerformedDiagnosis.diseaseStatusCode WHERE PerformedDiagnosis > AssessedResultRelationship > PerformedObservation > PerformedClinicalinterpretation.value = \"best result\" AND PerformedDiagnosis.value = \"peripheral neuropathy\"","url":null,"context":"NHLBI"},{"name":"Specify the best response of peripheral neuropathy to the HCT","type":"Alternate Question Text","description":"Specify the best response of peripheral neuropathy to the HCT","url":null,"context":"NHLBI"},{"name":"Specify the best response of peripheral neuropathy to the HCT","type":"Application Standard Question Text","description":"Specify the best response of peripheral neuropathy to the HCT","url":null,"context":"NHLBI"},{"name":"Specify the best response of peripheral neuropathy to the HSCT","type":"Alternate Question Text","description":"Specify the best response of peripheral neuropathy to the HSCT","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F3E1DA4-B3E1-419D-E040-BB89AD4354A5","latestVersionIndicator":"Yes","beginDate":"2010-02-10","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-02-10","modifiedBy":"KUMMEROA","dateModified":"2021-06-17","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}